Weill Cornell Medicine CHI3L1 compound 1-7

Weill Cornell Medicine CHI3L1 compound 1-7: sourced facts only. name: "Primary screening identified seven hits, with compounds 1-4 and 1-7 validated as CHI3L1 binders (Kd = 10.4 ± 1.0 μM and 7.40 ± 0.78 μM, respectively)." [PMID:41192685]; target: "Primary screening identified seven hits, with compounds 1-4 and 1-7 validated as CHI3L1 binders (Kd = 10.4 ± 1.0 μM and 7.40 ± 0.78 μM, respectively)." [PMID:41192685]; developer: "Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA." [PMID:41192685]; stage: "Importantly, functional evaluation in a multicellular 3D glioblastoma (GBM) spheroid model demonstrated that compound 1-7 potently reduced spheroid viability and inhibited STAT3 phosphorylation, outperforming both compound 1-4 and the known CHI3L1-STAT3 disruptor hygromycin B (HB)." [PMID:41192685]